Hikma Pharmaceuticals PLC 2021 SR
The report highlights Hikma's sustainability progress in 2021, focusing on four pillars: advancing health and wellbeing, empowering people, protecting the environment, and building trust through quality. Key achievements include donating $3.2 million in medicines, establishing a 25% reduction target for Scope 1 and 2 emissions by 2030, and launching a new culture framework. The company also conducted its first internal materiality assessment and aligned its disclosures with TCFD and UNGC principles.
Company: Hikma Pharmaceuticals PLC
Sector: Manufacturing
Country: United Kingdom
Year: 2021
Type: SR
Pages: 38
Back to company
Hikma Pharmaceuticals PLC
Sustainability Report
The report highlights Hikma's sustainability progress in 2021, focusing on four pillars: advancing health and wellbeing, empowering people, protecting the environment, and building trust through quality. Key achievements include donating $3.2 million in medicines, establishing a 25% reduction target for Scope 1 and 2 emissions by 2030, and launching a new culture framework. The company also conducted its first internal materiality assessment and aligned its disclosures with TCFD and UNGC principles.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2021
Reporting Period
Jan 1, 2021 - Dec 31, 2021
Fiscal Year
2021
Published
Feb 1, 2022
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
Sustainable Development Goals
Other Standards
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 3:
Energy Consumption
Water Consumption
Total Waste
Employees